Clinical Trials Logo

Intraabdominal Infections clinical trials

View clinical trials related to Intraabdominal Infections.

Filter by:

NCT ID: NCT00952796 Completed - Clinical trials for Intra-abdominal Infection

A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections

Start date: January 2009
Phase: Phase 4
Study type: Interventional

On the basis of monotherapy for intra-abdominal infection, the investigators are conducting this study to identify the difference of drug efficacy between ampicillin/sulbactam and moxifloxacin.

NCT ID: NCT00929643 Completed - Clinical trials for Complicated Intra-Abdominal Infection

Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections

Start date: November 2008
Phase: N/A
Study type: Observational

The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial antibiotic empiric therapy on pharmacological and total healthcare costs for these patients in Greece.

NCT ID: NCT00914888 Withdrawn - Clinical trials for Complicated Intra-Abdominal Infection

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia (CAP).

NCT ID: NCT00860587 Active, not recruiting - Clinical trials for Complicated Intra-Abdominal Infections

Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections

Bakki
Start date: February 2006
Phase: N/A
Study type: Observational

The objectives of the study were: 1. To study risk factors for colonization and infection with antibiotic resistant bacteria among patients with severe IAI before and after antibiotic treatment and surgical intervention. 2. To study species changes in the rectal flora among patients with severe IAI before and after antibiotic treatment and surgical intervention. 3. To review guidelines for antibiotic use in participating units. 4. To evaluate surgical antibiotic prophylaxis and treatment in relation to risk for colonization and infection with antibiotic resistant bacteria among patients with severe IAI 5. To use the results from the study in the process of a more appropriate use of antibiotics in participating units and care of patients with severe IAI. 6. To study the dynamics of extended-spectrum beta-lactamase producing and wild-type Enterobacteriaceae in patients with suspected severe intra abdominal infections before, during and after antibiotic treatment.

NCT ID: NCT00827541 Completed - Clinical trials for Intra-Abdominal Infections

Post-Authorization Study Evaluating Safety Of Tigecycline

HORUS
Start date: August 2008
Phase: N/A
Study type: Observational

This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and patients' conditions, in order to assess the "real incidence" of adverse events related with tigecycline in these patients.

NCT ID: NCT00769171 Completed - Clinical trials for Infection, Intra-abdominal

Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)

DRAGON
Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra abdominal infections. In view of the fact that intra abdominal infections are typically polymicrobial and are often treated empirically, the selected antibacterial agent must cover the likely spectrum of bacterial pathogens. Combination antibiotics therapy has been widely used with great success.

NCT ID: NCT00752219 Completed - Clinical trials for Complicated Intra-abdominal Infections

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Start date: March 31, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.

NCT ID: NCT00683332 Completed - Clinical trials for Complicated Intra-abdominal Infections

Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

Start date: April 2007
Phase: N/A
Study type: Observational

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

NCT ID: NCT00657566 Completed - Peritonitis Clinical Trials

SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The major hypothesis to be tested is that the treatment of intraabdominal infections that have been adequately treated operatively or by percutaneous techniques with three to five days of antibiotics will result in outcomes equivalent to the current standard where treatment is carried out until the patient has returned to normal (normal white blood cell count, temperature, and intestinal function), and that patients treated for three to five days will receive fewer days of antibiotics than the control group that has traditionally received seven to 14 days of treatment.

NCT ID: NCT00630513 Completed - Clinical trials for Intra-Abdominal Infection

T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam

TEA
Start date: January 2008
Phase: Phase 4
Study type: Interventional

The aim of the study was to compare the activity (efficacy and safety) of Ertapenem administered according to a short treatment for three days versus a short treatment for three days with AS in patients with an community acquired IAI of mild to moderate severity.